Antitubercular Drug Therapy – Past, Present and Future ::Book:: Science Publishing Group

Antitubercular Drug Therapy – Past, Present and Future

K. Purna Nagasree, M. Murali Krishna Kumar © by the authors

ISBN: 978-1-940366-14-2

Published Date: July, 2016

Pages: 138

Paperback: $95

Publisher: Science Publishing Group

Publication Status: Published

To purchase hard copies of this book, please email: book@sciencepublishinggroup.com

Book Description

This book deals with the introduction of tuberculosis, its worldwide problems, resistance and its posing threat, the available drugs and drug targets. Special emphasis on the threats of multidrug resistance and some methods to overcome it.

Author Introduction

Dr. K. Purna Nagasree DST, Women Scientist -A, Principal Investigator, College of Pharmaceutical Sciences, Andhra University, Visakhapatnam - 530 003, Andhra Pradesh, India.
Dr. M. Murali Krishna Kumar Assistant Professor, College of Pharmaceutical Sciences, Andhra University, Visakhapatnam - 530 003, Andhra Pradesh, India.

Table of Contents

The Whole Book
Download
FrontMatter
Download
Chapter 1 Introduction
Download
1. 1.1 History of Tuberculosis
2. 1.1.1 Discovery of the Pathogen
3. 1.1.2 Tuberculosis: Global Scenario
4. 1.2 Etiology and Pathophysiology
5. 1.2.1 M. Tuberculosis (MTB) Complex
6. 1.2.2 Structural Complexity of M. Tuberculosis Cell Wall
Chapter 2 Chemotherapeutic Agents Used for Tuberculosis
Download
1. 2.1 History
2. 2.2 Post Antibiotic ERA
3. 2.2.1 Streptomycin (SM) and Other Aminoglycoside Antibiotics
4. 2.2.2 Isoxyl (Thiocarlide) & Thiacetazone
5. 2.2.3 Isoniazid (INH)
6. 2.2.4 Pyrazinamide (PZA)
7. 2.2.5 P-Aminosalicylic Acid (PAS)
8. 2.2.6 Ethambutol (EMB)
9. 2.2.7 Cycloserine
10. 2.2.8 Rifampicin (RMP)
11. 2.2.9 Fluoroquinolones
12. 2.3 Conclusions
Chapter 3 New Drugs for Treating Tuberculosis in the Clinics and Clinical Trials - An Update
Download
1. 3.1 Drugs in Discovery and Development Stages
2. 3.1.1 Diamines (SQ109)
3. 3.1.2 Nitroimidazofurans and Nitroimidazopyrans
4. 3.1.3 Oxazolidinones
5. 3.1.4 Diarylquinolines (TMC207, SIRTURO^TM)
6. 3.2 Preclinical Agents
7. 3.2.1 Clofazimine and its Analogues
8. 3.2.2 Diarylpyrrole Derivatives
9. 3.2.3 BTZ043 and Its Analogues
10. 3.2.4 Imidazopyridine Amides
11. 3.2.5 Sudoterb (Pyrrole, LL-4858)
12. 3.2.6 Peptideformylase Inhibitor BB-3497
13. 3.2.7 Phenothiazines
14. 3.3 Conclusions
Chapter 4 Drug Resistance in Mycobacterium Tuberculosis
Download
1. 4.1 Major Mechanisms Involved in Thedevelopment of Drug Resistance in Microorganisms
2. 4.1.1 Drug - Resistant Tuberculosis
3. 4.1.2 Multi-Drug Resistant Tuberculosis (MDR-TB)
4. 4.1.3 Extensive-Drug Resistant Tuberculosis (XDR-TB)
5. 4.1.4 Basic Concepts in the Development of Drug-Resistant TB
6. 4.2 Molecular Basis of Drug Action and Resistance
7. 4.2.1 Isoniazid (INH)
8. 4.2.2 Rifampicin (RMP)
9. 4.2.3 Pyrazinamide (PZA)
10. 4.2.4 Ethambutol (EMB)
11. 4.2.5 Aminoglycosides (Streptomycin (SM)/Kanamycin (KM)/Amikacin (AMK)/Capreomycin CPM)
12. 4.2.6 Fluoroquinolones (FQ)
13. 4.2.7 Ethionamide (ETH)/Prothionamide (PTH) and Thioamides
14. 4.2.8 Oxazolidinones
15. 4.2.9 Cycloserine
16. 4.3 New Drugs, New Targets and New Resistance Mechanisms
17. 4.3.1 Nitroimidazoles
18. 4.3.2 SQ109
19. 4.3.3 Bedaquiline (TMC207, R207910, Sirturo^®)
20. 4.3.4 Benzothiazinones
21. 4.4 Conclusions
Chapter 5 Strategies for Anti-Tubercular Drug Development
Download
1. 5.1 Cell Wall Components Synthesis and Assemblage
2. 5.1.1 Biosynthesis of Mycolic Acids and Other Lipids
3. 5.1.2 Mycobacteria Possessing FAS-I and FAS-II Enzymes
4. 5.2 Targets in Mycolic Acid Biosynthesis
5. 5.2.1 INH A and Maba
6. 5.2.2 Kas A and Kas B
7. 5.2.3 Β-Ketoacyl-ACP Synthaseinhibitors
8. 5.2.4 FadD32 – AccD4 System
9. 5.2.5 Methyltransferases
10. 5.2.6 Polyketide Synthase System (Pks)
11. 5.2.7 Mmpl3 Transporter Protein
12. 5.2.8 Biosynthesis of Mycolyl-Arabinogalactan-Peptidoglycan Complex
13. 5.3 Drug Targets for Tuberculosis
14. 5.3.1 Peptidoglycan Biosynthesis
15. 5.3.2 Protein Synthesis as a Target
16. 5.3.3 Decaprene Biosynthesis
17. 5.3.4 The MEP Pathway as a Drug Target
18. 5.4 Enzymes Involved in Amino Acids or Co-Factor Biosynthesis
19. 5.4.1 Pantothenatesynthetase
20. 5.4.2 Quinolinatephosphoribosyltransferase (QAPRTase)
21. 5.4.3 Shikimate Kinase (SK)
22. 5.4.4 Thymidylate Kinase
23. 5.5 Targets in DNA Biosynthesis and Metabolism
24. 5.5.1 Ribonucleotide Reductases
25. 5.5.2 DNA Ligase
26. 5.5.3 DNA Topoisomerase
27. 5.5.4 Respiratory Chain Inhibitors
28. 5.6 Miscellaneous Targets
29. 5.6.1 Isocitratelyase (ICL)
30. 5.6.2 Mycobacterium Protein Tyrosine Phosphatase B (mPTPB)
31. 5.6.3 Carbonic Anhydrase
32. 5.6.4 Mycobacterial Thioredoxin Reductase (MtTrxR)
33. 5.6.5 Glutamine Synthetase (GS)
34. 5.6.6 Cysteine Biosynthetic Pathway
35. 5.6.7 Acetohydroxyacid Synthase (AHAS)
36. 5.7 Conclusions
BackMatter
Download